304 related articles for article (PubMed ID: 29285547)
1. Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.
Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
JAMA Oncol; 2018 Mar; 4(3):326-332. PubMed ID: 29285547
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
3. Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?
Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
JCO Oncol Pract; 2020 Aug; 16(8):e779-e790. PubMed ID: 32196423
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
Saluja R; Everest L; Cheng S; Cheung M; Chan KKW
JAMA Oncol; 2019 Aug; 5(8):1188-1194. PubMed ID: 31095255
[TBL] [Abstract][Full Text] [Related]
5. Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvals.
Lanitis T; Ambavane A; Zheng Y; Schlichting M; Phatak H
Future Oncol; 2019 Dec; 15(35):4057-4067. PubMed ID: 31687852
[No Abstract] [Full Text] [Related]
6. Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors.
Vivot A; Créquit P; Porcher R
J Natl Cancer Inst; 2019 May; 111(5):519-521. PubMed ID: 30615127
[TBL] [Abstract][Full Text] [Related]
7. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.
Cushman TR; Caetano MS; Welsh JW; Verma V
Immunotherapy; 2018 Aug; 10(10):851-0. PubMed ID: 30073899
[TBL] [Abstract][Full Text] [Related]
8. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
Flaig TW
J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
10. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
[TBL] [Abstract][Full Text] [Related]
11. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
12. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Haslam A; Prasad V
JAMA Netw Open; 2019 May; 2(5):e192535. PubMed ID: 31050774
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
14. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Lee HT; Lee SH; Heo YS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
[TBL] [Abstract][Full Text] [Related]
15. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
Gkolfinopoulos S; Mountzios G
Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
[No Abstract] [Full Text] [Related]
16. Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration.
Liang F; Zhang S; Wang Q; Li W
BMC Cancer; 2020 Aug; 20(1):823. PubMed ID: 32867707
[TBL] [Abstract][Full Text] [Related]
17. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
Hoering A; Durie B; Wang H; Crowley J
Future Oncol; 2017 Jun; 13(13):1181-1193. PubMed ID: 28395525
[TBL] [Abstract][Full Text] [Related]
18. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Pediatric Oncology: An Overview of Therapy Types and Nursing Implications.
Warren CB
Clin J Oncol Nurs; 2018 Dec; 22(6):649-655. PubMed ID: 30452014
[TBL] [Abstract][Full Text] [Related]
20. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.
Thompson JA
J Natl Compr Canc Netw; 2018 May; 16(5S):594-596. PubMed ID: 29784734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
